Catalyst Wire Dossier Catalyst Wire Dossier

AZD6244 (selumetinib)

selumetinib · AstraZeneca
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for AZD6244 (selumetinib), covering 2014-07-02 to 2015-12-09. Get the full timeline:

Most recent: Clinical Trial Update: Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients [Phase 2]

See pricing